Who are Two-week course of radiation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Androgen blockade + radiation therapy, Radiation Therapy, Radiotherapy and PCV chemotherapy, RT+CETUXIMAB, Concurrent chemo-radiotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/two-week-course-of-radiation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Two-week course of radiation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Two-week course of radiation (Two-week course of radiation) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiation therapy. Area: Oncology.

phase 3 Radiation therapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Two-week course of radiation (Two-week course of radiation) — Jong Hoon Lee. Ionizing radiation damages cancer cell DNA to inhibit tumor growth and induce cell death.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Two-week course of radiation TARGET	Two-week course of radiation	Jong Hoon Lee	phase 3	Radiation therapy
Androgen blockade + radiation therapy	Androgen blockade + radiation therapy	Université de Sherbrooke	phase 3	Androgen receptor antagonist + radiation therapy (combination)	Androgen receptor (AR)
Radiation Therapy	Radiation Therapy	M.D. Anderson Cancer Center	phase 3	Radiation therapy / Physical modality
Radiotherapy and PCV chemotherapy	Radiotherapy and PCV chemotherapy	Hospices Civils de Lyon	phase 3	Combination chemotherapy and radiation therapy
RT+CETUXIMAB	RT+CETUXIMAB	Associazione Volontari Pazienti Oncologici	phase 3	EGFR inhibitor (monoclonal antibody) + radiation therapy combination	EGFR (epidermal growth factor receptor)
Concurrent chemo-radiotherapy	Concurrent chemo-radiotherapy	Sun Yat-sen University	phase 3	Combination chemotherapy and radiation therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiation therapy class)

Jong Hoon Lee · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Two-week course of radiation — Competitive Intelligence Brief. https://druglandscape.com/ci/two-week-course-of-radiation. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab